P-selectin and Platelet activating factor in acute patients with deep venous thrombosis
10.3760/cma.j.issn.1673-4203.2010.10.005
- VernacularTitle:下肢深静脉血栓形成患者P-选择素与血小板活化因子的变化及意义
- Author:
Jiang WU
;
Xiaoyan LENG
;
Yunfeng SONG
- Publication Type:Journal Article
- Keywords:
Deep venous thrombosis;
P-selectin;
Platelet activating factor
- From:
International Journal of Surgery
2010;37(10):659-661
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the status of P-selectin and platelet activating factor(PAF) in vivo in patients with deep venous thrombosis(DVT) and to observe their changes under interneving of medicines.Methods P-selectin and PAF of fourty patients and twenty normal subjects were fluorescence labled with corresponding monoclonal antibodies by flow cytometry( FCM ) and immunologic method respectively. Results P-selectin and PAF in patients with DVT were higher than that in normal subjects in early period of the disease, and they significantly decreased in different time after patients were treated. P-selectin was significantly different between patients who received sodium ozagrel treatment and those who not (P ＜0.05 ), but PAF was similar( P ＞ 0. 05 )after fourteen days. One month later, P-selectin and D-dimer in DVT patients were lower than before. However, the positive rate of P-selectin of DVT was still higher than normal subjects. Conclusions The platelet is activated in vivo in patients with DVT, so does fibrinolysis. Sodium ozagrel can decrease activity of platelet. P-selectin and PAF may be used diagnostic markers. Post-discharge patients are still at high-risk and must be regularly followed-up.
